A Phase 2/3 interventional study of Fenofibrate 200mg and Placebo in Primary Biliary Cholangitis, sponsored by Xijing Hospital of Digestive Diseases. Recruiting at 12 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Xijing Hospital of Digestive Diseases · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing fenofibrate in Liver Cirrhosis, Biliary — 7 open to participants now, 9 under way, 8 of them phase 3. Fenofibrate · Liver Cirrhosis, Biliary.
Among the 13 studies testing fenofibrate in Liver Cirrhosis, Biliary, this one is the 8th largest by planned enrollment, is one of 3 that started in 2023, is one of 3 in phase 2/3, and was the 6th registered.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
Browse Liver Cirrhosis, Biliary studies →7 of the 13 studies testing fenofibrate in Liver Cirrhosis, Biliary are open now, in 1 country. Recruiting first, the newest first:
Xijing Hospital of Digestive Diseases · Sites in China
Ages 18–75
Xijing Hospital of Digestive Diseases · Sites in China
Ages 18–75
Xijing Hospital of Digestive Diseases · Sites in China
Ages 18–75
Xijing Hospital of Digestive Diseases · Sites in China
Ages 18–75
Xijing Hospital of Digestive Diseases · Sites in China
Ages 18–75
By country, each count listing its studies:
Fenofibrate: first FDA approval 1993 (TRICOR (MICRONIZED)), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 9
First in 2011; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 104 is above the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.
Median enrollment 117 across the 13 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 4 most frequent:
Xijing Hospital of Digestive Diseases is the lead sponsor of 81 studies on the registry; 23 are open to participants now.
12 studies in Liver Cirrhosis, Biliary by Xijing Hospital of Digestive Diseases: 7 open now, 8 under way, 7 of them phase 3. Of 1 finished, 0 (0%) have results posted.
Among the 12 studies in Liver Cirrhosis, Biliary by Xijing Hospital of Digestive Diseases, this one is the 10th largest by planned enrollment, is one of 2 that started in 2023, is one of 2 in phase 2/3, and was the 7th registered.
Xijing Hospital of Digestive Diseases’s Liver Cirrhosis, Biliary studies by the year they started, since 2016.
1 of the studies testing fenofibrate in Liver Cirrhosis, Biliary that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06365424Phase 3Xijing Hospital of Digestive DiseasesFenofibrate in Patients With Primary Biliary Cholangitis (PBC) | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing fenofibrate in Liver Cirrhosis, Biliary, from their registry updates:
Among Xijing Hospital of Digestive Diseases’s 12 in Liver Cirrhosis, Biliary:
This tab as a report to print or save as PDF → With an account.
The main objectives of the study were to assess the effects of fenofibrate on serum alkaline phosphatase, as a composite endpoint and on safety in participants with primary biliary cholangitis (PBC).
This is a multi-center, randomized, placebo-controlled, parallel-group study that aims to assess the efficacy and safety of fenofibrate in patients with compensated cirrhosis PBC who had an inadequate biochemical response to UDCA. Fenofibrate or placebo 200 mg will be daily administered in combination with UDCA 13-15 mg/kg/d for 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female with a diagnosis of PBC, by at least two of the following criteria:
Diagnosis of compensated cirrhosis, as demonstrated by the presence of ≥ 1 of the following 4 diagnostic factor
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 tablet/ day and UDCA 13-15mg/kg/day for 12 months
Drug: Placebo · Drug: UDCA
Fenofibrate 200 mg/day and UDCA 13-15mg/kg/day for 12 months
Drug: Fenofibrate 200mg · Drug: UDCA
Fenofibrate 200mg/day
1 tablet/ day
UDCA 13-15mg/kg/day
Percentage of patients with biochemical response
The normalisation of Alkaline Phosphatase
Time frame: 48 weeks
Percentage of patients having biochemical response
The normalisation of Alkaline Phosphatase at 4, 12, 24, and 36 weeks.
Time frame: 4, 12, 24 and 36weeks
Assessment of the pruritus and fatigue
Change From Baseline in Fatigue and Pruritus as Assessed by Visual Analogue Scale (VAS) Total Score for Fatigue and Pruritus. (0-10, higher scires mean a worse outcome)
Time frame: 4, 12, 24, 36, and 48 weeks
Percentage of patients having biological or clinical adverse events
Increase of creatinine
Time frame: 4, 12, 24, 36, and 48 weeks
Percentage of patients having biological or clinical adverse events
Increase Blood urea nitrogen
Time frame: 4, 12, 24, 36, and 48 weeks
Percentage of patients having biological or clinical adverse events
Increase of creatine kinase
Time frame: 4, 12, 24, 36, and 48 weeks
Percentage of patients having biological or clinical adverse events
Increase ALT and AST.
Time frame: 4, 12, 24, 36, and 48 weeks
Survival without transplantation and hepatic impairment
Occurrence of ascites, variceal bleeding, hepatic encephalopathy, liver-transplantation, or death.
Time frame: 48 weeks
Started Feb 2023 (actual). Primary completion is estimated for Dec 2027, 57 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fenofibrate
Xijing Hospital of Digestive Diseases